RxDoctor Payments Data

Kristin Barone

Nurse Practitioner · Hamilton, NJNPI 1902534779

Payments from drug & device makers

$841in general payments, 2019–2025

Across 14 payments — averaging $60.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Photocure Inc$248
  • Medtronic$149
  • Urogen Pharma, Inc.$125
  • Johnson & Johnson$125
  • ABC Home Medical Supply, Inc.$57
  • Coloplast$50
  • plus $88 from 4 others

What the payments were for

  • Food & beverage$841100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Photocure Inc1$248
Medtronic1$149
Urogen Pharma, Inc.1$125
Johnson & Johnson1$125
ABC Home Medical Supply, Inc.2$57
Coloplast3$50
Sumitomo Pharma America, Inc.2$30
180 Medical, Inc.1$25
Astellas Pharma US Inc1$19
Bayer1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$841 in reported general payments places this provider in the 75th percentile of 2,138 nurse practitioner providers in New Jersey.

See all nurse practitioner providers in New Jersey

Medicare billing

Part B allowed, 2024
$110,657
Medicare patients
590
Services billed
1,743

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron118$79,979
GemtesaVibegron25$15,117
Solifenacin Succinate108$3,787
Estradiol39$3,716
Tamsulosin Hcl196$3,052
Methenamine Hippurate14$1,098
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst54$862
Finasteride70$733
Oxybutynin Chloride ErOxybutynin Chloride35$666
Tolterodine Tartrate ErTolterodine Tartrate12$543
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip23$535
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim119$209
Alfuzosin Hcl ErAlfuzosin Hcl13$201
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav16$120
Levofloxacin30$114

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$19$79,979118 claims
Sumitomo Pharma America, Inc.Gemtesa$30$15,11725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,138 nurse practitioner providers in New Jersey.

Other nurse practitioner in Hamilton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →